Pharmaceutical Executive-04-01-2022

How early stage can help set you up for big stage.

With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.

With an increase in drug development, why purpose should be the pharma industry’s secret advantage in the global talent shortage, as the COVID-19 crisis transitions into the endemic stage.

Reshma Kewalramani, MD, FASN, chief executive officer and president of Vertex Pharmaceuticals talks about how she supports the efforts of DE&I within and outside her organization.

Robert McMahon, former president of Merck US Human Health, shares some of the challenges leaders face when grappling with how to transform their organizations to embrace DE&I.

Benchmark study across healthcare sectors measures progress in advancing women and people of color into top leadership roles.

Saving and transforming as many patients’ lives as possible has been the driving force behind Beth Seidenberg’s audacious career, where she has excelled as a doctor, researcher, and venture capitalist.

What will current stranglehold mean for industry down the line?

Tackling the subjective limits of value proposition.

Why their influence on employee representation matters for pharma.

Exploring the market’s emergence on the global stage.

Fresh round of discussions around health technology assessment.

Pharm Exec introduces new monthly columns.

Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.

Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.

Quality metrics, more domestic production aim to avoid supply disruptions and drug shortages.